Key result
Real-world LAAC in NVAF yields ~5% less major bleeding and fewer strokes than PROTECT AF.
Why the study?
Outcomes and costs of left atrial appendage closure with the Watchman device compared to oral anticoagulation therapies in NVAF patients were not fully characterized in both randomized and real-world settings.
Does left atrial appendage closure with the Watchman device improve clinical outcomes and reduce costs compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
Meta-Analysis (n=112)
Does left atrial appendage closure with the Watchman device improve clinical outcomes and reduce costs compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
Left atrial appendage closure in a real-world setting for non-valvular atrial fibrillation may result in lower stroke and bleeding rates than in clinical trials, and achieves cost savings over 10 years compared to oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Real-world LAAC may lower stroke/bleeding versus trials with 10-year savings; extends PROTECT AF data but leaves efficacy open for RCTs.
AIMS: The aim of this study was to analyse randomized controlled study and real-world outcomes of patients with non-valvular atrial fibrillation (NVAF) undergoing left atrial appendage closure (LAAC) with the Watchman device and to compare costs with available antithrombotic therapies. METHODS AND Outcomes from PROTECT AF and registry study LAAC were compared with warfarin, dabigatran, rivaroxaban, apixaban, aspirin, and no treatment using a network meta-analysis. Costs were estimated over a 10-year horizon. Uncertainty was assessed using sensitivity analyses. The procedural success rate was 92% (103/112). Follow-up was 24.1 ± 4.6 months, during which annual rates of stroke, major bleeding, and all-cause mortality were 0.9% (2/223 patient-years), 0.9% (2/223 patient-years), and 1.8% (4/223 patient-years), respectively. Anticoagulant therapy was successfully stopped in 91.2% (93/102) of implanted patients by 12 months. results: mean absolute difference of stroke, 0.89% (P = 0.02) and major bleeding, 5.48% (P < 0.001). Left atrial appendage closure achieved cost parity between 4.9 years vs. dabigatran 110 mg and 8.4 years vs. warfarin. At 10 years, LAAC was cost-saving against all therapies (range £1162-£7194). CONCLUSION: Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.
No takes yet. Share an insight, caveat, or question.
Panikker et al. (2016) conducted a meta-analysis in Non-valvular atrial fibrillation (NVAF) (n=112). Left atrial appendage closure (LAAC) with the Watchman device vs. Warfarin, dabigatran, rivaroxaban, apixaban, aspirin, no treatment, and PROTECT AF trial results was evaluated on Stroke (mean absolute difference 0.89%, p=0.02). Real-world left atrial appendage closure in NVAF had lower stroke and major bleeding rates than PROTECT AF, and achieved cost parity.
Synapse has enriched 10 related papers. Consider them for comparative context: